Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.

@article{Sitbon2005SurvivalIP,
  title={Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.},
  author={Olivier Sitbon and Vallerie V Mclaughlin and David B. Badesch and Robyn J. Barst and Carri Black and Nazzereno Gali{\`e} and Michel Humbert and Maurizio Rainisio and Lewis J. Rubin and G{\'e}rald Simonneau},
  journal={Thorax},
  year={2005},
  volume={60 12},
  pages={1025-30}
}
BACKGROUND The oral dual endothelin receptor antagonist bosentan improves exercise capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its use could delay starting intravenous epoprostenol, a life saving treatment. METHODS Survival in patients with functional class III idiopathic pulmonary arterial hypertension (PAH) treated with bosentan in clinical trials was compared with historical data from similar patients treated with epoprostenol in the clinic… CONTINUE READING
74 Citations
10 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 74 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Similar Papers

Loading similar papers…